Literature DB >> 25050826

Inactivation of TEM-1 by avibactam (NXL-104): insights from quantum mechanics/molecular mechanics metadynamics simulations.

Jacopo Sgrignani1, Giovanni Grazioso, Marco De Amici, Giorgio Colombo.   

Abstract

The fast and constant development of drug-resistant bacteria represents a serious medical emergence. To overcome this problem, the development of drugs with new structures and modes of action is urgently needed. In this context, avibactam represents a promising, innovative inhibitor of beta-lactamases with a novel molecular structure compared to previously developed inhibitors, showing a promising inhibitory activity toward a significant number of beta-lactamase enzymes. In this work, we studied, at the atomistic level, the mechanisms of formation of the covalent complex between avibactam and TEM-1, an experimentally well-characterized class A beta-lactamase, using classical and quantum mechanics/molecular mechanics (QM/MM) simulations combined with metadynamics. Our simulations provide a detailed structural and energetic picture of the molecular steps leading to the formation of the avibactam/TEM-1 covalent adduct. In particular, they support a mechanism in which the rate-determining step is the water-assisted Glu166 deprotonation by Ser70. In this mechanistic framework, the predicted activation energy is in good agreement with experimental kinetic measurements. Additionally, our simulations highlight the important role of Lys73 in assisting the Ser70 and Ser130 deprotonations. While based on the specific case of the avibactam/TEM-1, the simple protocol we present here can be immediately extended and applied to the study of covalent complex formation in different enzyme-inhibitor pairs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25050826     DOI: 10.1021/bi500589x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Avibactam and inhibitor-resistant SHV β-lactamases.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

2.  Mechanism of proton transfer in class A β-lactamase catalysis and inhibition by avibactam.

Authors:  Orville A Pemberton; Radwan E Noor; Vasantha Kumar M V; Ruslan Sanishvili; M Trent Kemp; Fiona L Kearns; H Lee Woodcock; Ioannis Gelis; Yu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-02       Impact factor: 11.205

Review 3.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553

Review 4.  Exploring Additional Dimensions of Complexity in Inhibitor Design for Serine β-Lactamases: Mechanistic and Intra- and Inter-molecular Chemistry Approaches.

Authors:  Focco van den Akker; Robert A Bonomo
Journal:  Front Microbiol       Date:  2018-04-05       Impact factor: 5.640

5.  Analysis of a novel class A β-lactamase OKP-B-6 of Klebsiella quasipneumoniae: structural characterisation and interaction with commercially available drugs.

Authors:  Reinaldo Bellini; Isabella Alvim Guedes; Luciane Prioli Ciapina; Ana Tereza Ribeiro de Vasconcelos; Laurent Emmanuel Dardenne; Marisa Fabiana Nicolás
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-09-23       Impact factor: 2.747

6.  Inhibition of Klebsiella β-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study.

Authors:  Nikhil P Krishnan; Nhu Q Nguyen; Krisztina M Papp-Wallace; Robert A Bonomo; Focco van den Akker
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

7.  Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition.

Authors:  Hwanho Choi; Robert S Paton; Hwangseo Park; Christopher J Schofield
Journal:  Org Biomol Chem       Date:  2016-04-26       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.